<DOC>
	<DOCNO>NCT00316771</DOCNO>
	<brief_summary>This 6 arm study evaluate efficacy safety different dos P38 Inhibitor ( 4 ) patient RA currently inadequate clinical response methotrexate . Patients randomize receive P38 Inhibitor ( 4 ) ( 50,150 300 qd po , 25 75 bid po ) placebo , remain stable dose methotrexate . The anticipated time study treatment &lt; 3 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study P38 Inhibitor ( 4 ) Patients With Active Rheumatoid Arthritis ( RA ) Stable Methotrexate Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>adult patient &gt; =18 year age ; active rheumatoid arthritis ; current inadequate clinical response methotrexate . receive diseasemodifying antirheumatic drug , exception hydroxychloroquine chloroquine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>